Advertisement

Topics

Dyskinesia - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Dyskinesia - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 149-page report is available in PDF from $2000.

Dyskinesia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dyskinesia - Pipeline Review, H1 2015’, provides an overview of the Dyskinesia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dyskinesia Overview 10
Therapeutics Development 11
Pipeline Products for Dyskinesia - Overview 11
Pipeline Products for Dyskinesia - Comparative Analysis 12
Dyskinesia - Therapeutics under Development by Companies 13
Dyskinesia - Therapeutics under Investigation by Universities/Institutes 16
Dyskinesia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Dyskinesia - Products under Development by Companies 20
Dyskinesia - Products under Investigation by Universities/Institutes 23
Dyskinesia - Companies Involved in Therapeutics Development 24
Adamas Pharmaceuticals, Inc. 24
Addex Therapeutics Ltd 25
Advicenne Pharma 26
Amarantus Bioscience Holdings, Inc. 27
Astraea Therapeutics, LLC 28
Auspex Pharmaceuticals, Inc. 29
BioMarin Pharmaceutical Inc. 30
Catalyst Pharmaceutical Partners, Inc. 31
Contera Pharma ApS 32
EpiVax, Inc. 33
Heptares Therapeutics Ltd. 34
Integrative Research Laboratories Sweden AB 35
Ipsen S.A. 36
Medicure Inc. 37
Medy-Tox Inc. 38
Merz Pharmaceuticals GmbH 39
Neurim Pharmaceuticals Ltd 40
Neurocrine Biosciences, Inc. 41
Neurolixis Inc. 42
Novartis AG 43
Osmotica Pharmaceutical Corp. 44
Otsuka Holdings Co., Ltd. 45
Santhera Pharmaceuticals Holding AG 46
SciFluor Life Sciences, LLC 47
Synchroneuron Inc. 48
Targacept, Inc. 49
Upsher-Smith Laboratories, Inc. 50
Dyskinesia - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
abobotulinumtoxin A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
abobotulinumtoxin A next generation - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
acamprosate calcium SR - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ADV-6979 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
amantadine hydrochloride ER - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
amantadine hydrochloride ER - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AQW-051 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AT-127 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AT-326 - Drug Profile 74
Product Description 74
Mechanism of Action 74 For more information open Dyskinesia - Pipeline Review, H1 2015.

SKU: GMDHC6258IDB

Original Article: Dyskinesia - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Dyskinesia - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...